Mechanism of Blood‐Heart‐Barrier Leakage: Implications for COVID‐19 induced Cardiovascular Injury

ABSTRACT

Although blood‐heart‐barrier (BHB) leakage is the hallmark of congestive (cardio‐pulmonary) heart failure (CHF), the primary cause of death in elderly, and during viral myocarditis resulting from the novel coronavirus such as the severe acute respiratory syndrome novel corona virus 2 (SARS‐CoV‐2) known as COVI‐19, the mechanism is unclear. The goal of this project is to determine the mechanism BHB in CHF. Endocardial endothelium (EE) is the BHB against leakage of blood from endocardium to the interstitium;however, this BHB is broken during CHF. Previous studies from our laboratory, and others have shown a robust activation of matrix metalloproteinase‐9 (MMP‐9) during CHF. MMP‐9 degrades connexins leading to EE dysfunction. We demonstrated juxtacrine coupling of EE with myocyte, and mitochondria (Mito) but how it works still remains at large. To test whether activation of MMP‐9 causes EE barrier dysfunction, we hypothesized that if that were the case then treatment with hydroxychloroquine (HCQ) could, in fact, inhibit MMP‐9, and thus preserve the EE barrier/juxtacrine signaling, and synchronous endothelial‐myocyte coupling. To determine this, CHF was created by aorta‐vena cava fistula (AVF) employing the mouse as a model system. The sham, and AVF mice were treated with HCQ. Cardiac hypertrophy, tissue remodeling‐induced mitochondrial‐myocyte, and endothelial‐myocyte contractions were measured. Microvascular leakage was measured using FITC‐albumin conjugate. The cardiac function was measured by echocardiography (Echo). Results suggest that MMP‐9 activation, endocardial endothelial leakage, endothelial‐myocyte (E‐M) uncoupling, dyssynchronous mitochondrial fusion‐fission (Mfn2/Drp1 ratio) and mito‐myocyte uncoupling in AVF heart failure were found to be rampant however, treatment with HCQ successfully mitigated some of the deleterious cardiac alterations during CHF. The findings have direct relevance to the gamut of cardiac manifestations, and the resultant phenotypes arising from the ongoing complications of COVID‐19 in human subjects.